BioVie Announces Efficacy Data from Phase 3 Trial of

Positive Trending Data from 57 Per-Protocol Patients Suggest NE3107 is Biologically Active and May Have Impact on Cognitive, Functional, and Biomarker...

Related Keywords

United States ,Sweden ,Gothenburg ,Vastra Gotalands Lan ,Americans ,Suzanne Hendrix ,Melyssa Weible ,Joseph Palumbo ,Elixir Health Public Relations ,Office Of Scientific Investigations ,Office Of Scientific Investigation ,Nasdaq ,Biovie Inc ,Drug Administration ,Company Clinical Research Organization ,K Biovie Inc ,International Conference On Alzheimer ,Positive Trending Data ,Protocol Patients Suggest ,Biologically Active ,May Have Impact ,Identified Issues Relating ,Protocol Deviations ,Which Allowed ,Enrolled Patients ,Efficacy Analysis ,Sites Suspected ,Improprieties Have Been Referred ,Adaptive Feature ,Trial May Allow ,Continue Enrolling Patients ,Statistical Significance ,Host Conference Call ,Vie Inc ,Skin Blood ,Good Clinical Practice ,Scientific Investigations ,Modified Intent ,Prev Alz ,Clinical Dementia Rating Sum ,Neurofilament Light Chain ,Executive Vice President ,Chief Medical ,Disease Assessment Scale Cognitive ,Electronic Data Capture ,Clinical Research Organization ,Good Clinical Practices ,Statistical Analysis Plan ,Scientific Investigation ,Clinical Trial ,International Conference ,Related Neurological Disorders ,Investor Relations Inquiries ,Media Relations Inquiries ,Disease Assessment ,Nasdaq Bivi ,Biovie ,Nc ,